Oral ponesimod in relapsing–remitting multiple sclerosis: a randomised phase II trial

OBJECTIVE: This double-blind, placebo-controlled, dose-finding phase IIb study evaluated the efficacy and safety of ponesimod, an oral selective S1P(1) receptor modulator, for the treatment of patients with relapsing–remitting multiple sclerosis (RRMS). METHODS: 464 patients were randomised to recei...

Descripción completa

Detalles Bibliográficos
Autores principales: Olsson, Tomas, Boster, Aaron, Fernández, Óscar, Freedman, Mark S, Pozzilli, Carlo, Bach, Doris, Berkani, Ouali, Mueller, Markus S, Sidorenko, Tatiana, Radue, Ernst-Wilhelm, Melanson, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2014
Materias:
Multiple Sclerosis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4215282/
https://www.ncbi.nlm.nih.gov/pubmed/24659797
http://dx.doi.org/10.1136/jnnp-2013-307282

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4215282/
https://www.ncbi.nlm.nih.gov/pubmed/24659797
http://dx.doi.org/10.1136/jnnp-2013-307282

Ejemplares similares